Skin Vaccination Summit 2020

17-19 March 2020, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Provisional Conference Programme | Tuesday 17th March 2020

Welcome & Opening Remarks

SESSION 1:
OPENING PLENARY SESSION

Moderator: To be confirmed

Opening Keynote: Skin Delivery Overview
Speaker TBC
James Birchall
(Cardiff University, Cardiff, Wales, UK)

‘Targeting Skin Dendritic cells’
Esther C. de Jong
(Dept. Experimental Immunology, Amsterdam UMC, Amsterdam, The Netherlands)

‘Title TBC’
Joke Bouwstra
(LACDR, University of Leiden, Leiden, The Netherlands)

Coffee Break

SESSION 2:
GLOBAL

Moderator: To be confirmed

‘Understanding program needs and suitability of microarray patch technology for global health’
Jennifer Foster, Annie Rein-Weston, Collrane Frivold, Priyanka Bajaj, Shubham Kesharwani, Darin Zehrung and Courtney Jarrahian
(PATH, Seattle, Washington, USA)

‘The experience of intradermal administration of fractional dose inactivated poliovirus by the Global Polio Eradication Initiative (GPEI)’
Grace Macklin
(World Health Organization, Geneva, Switzerland)

‘Quantitative and qualitative assessment of different techniques of intradermal administration of fractional dose IPV in campaign setting in the Gambia’
Vishali Jeyaseelan
(World Health Organization, Geneva, Switzerland)

Lunch Break & Posters Set-Up

SESSION 3:
RESPONSES

Moderator: To be confirmed

‘Innate local response and tissue recovery following application of high-density microarray patches to human skin’
David A. Muller1, Joakim Henricson2,3, S. Ben Baker4, Totte Togö5, Cesar M. Jayashi4, Pierre A. Lemaire4, Angus Forster4, Paul R. Young1 and Christopher D. Anderson6,7
(1 School of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australia; 2 Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden; 3 Department of Emergency Medicine, Local Health Care Services in Central Östergötland, Sweden; 4 Vaxxas Pty Ltd, Translational Research Institute, Woolloongabba, Queensland, Australia; 5 Allergy Center Linköping, Region Östergötland, Sweden; 6 Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden; 7 Department of Clinical and Experimental Medicine, Linköping University, Region Östergötland, Sweden)

Staphylococcus aureus affects skin inflammation through specific molecular interactions with Langerhans cells’
N. van Sorge
(UMC Utrecht, Medical Microbiology, Utrecht, The Netherlands)

‘Cellular responses at the site of microarray patch influenza vaccine delivery in a randomized, controlled phase I clinical trial’
Alexandra C.I. Depelsenaire1*, Katey Witham1*, Margaret Veitch2, James W. Wells2, Christopher D. Anderson3, Jason D. Lickliter4, Steve Rockman5,6, Jesse Bodle5, Julian Hickling7, Germain J.P. Fernando1,8, Angus H. Forster1
(1 Vaxxas Pty Ltd, Brisbane, Queensland, Australia; 2 The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia; 3 Department of Clinical and Experimental Medicine, Linkoping University, Sweden; 4 Nucleus Network Pty Ltd, Melbourne, Victoria, Australia; 5 Seqirus Pty Ltd, Parkville, Victoria, Australia; 6 Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; 7 Working in Tandem Ltd, Cambridge, UK; 8 The University of Queensland, School of Chemistry & Molecular Biosciences, Faculty of Science, Brisbane, Queensland, Australia)

 

SVS 2020 Delegates

Login details will be supplied after you have registered for the event.


SVS 2020 Sponsors

  • ONdrugDELIVERY
  • PharmaJet
  • Vismederi
  • Nanopass

SVS 2020 Downloads

SVS 2020 Leaflet

SVS 2020 Mailing List

Name
E-mail Address
What is 3+2-1?